Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C
Launched by MAYO CLINIC · Aug 19, 2024
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
PRIMARY OBJECTIVES:
I. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with directly acting antiviral (DAA), and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic.
II. To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the hepatitis C virus (HCV) genotype.
III. To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA.
OUTLINE:...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals with chronic hepatitis C who are to begin therapy with DAA
- • Willing to submit a peripheral blood sample at baseline, end of therapy, 12 weeks after the end of therapy, and 52 weeks from baseline
- Exclusion Criteria:
- • Individuals with chronic hepatitis C who have cirrhosis
- • Individuals with chronic hepatitis C who have a past history of a lymphoproliferative disorder AND for which they received chemotherapy
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Sameer A. Parikh, M.B.B.S.
Principal Investigator
Mayo Clinic in Rochester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported